BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 5,000 shares of the company’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $88.38, for a total transaction of $441,900.00. Following the transaction, the chief executive officer now directly owns 238,564 shares in the company, valued at $21,084,286.32. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Wednesday, May 17th, Jean Jacques Bienaime sold 5,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $91.73, for a total transaction of $458,650.00.
  • On Monday, May 8th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $96.09, for a total transaction of $960,900.00.
  • On Thursday, April 27th, Jean Jacques Bienaime sold 5,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $95.72, for a total transaction of $478,600.00.
  • On Tuesday, April 25th, Jean Jacques Bienaime sold 5,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $94.00, for a total transaction of $470,000.00.
  • On Thursday, March 16th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $91.69, for a total transaction of $916,900.00.
  • On Friday, March 10th, Jean Jacques Bienaime sold 11,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.59, for a total transaction of $996,490.00.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded up 0.77% on Friday, reaching $88.00. 933,838 shares of the company’s stock were exchanged. The stock’s market capitalization is $15.36 billion. The firm’s 50 day moving average is $91.31 and its 200 day moving average is $88.68. BioMarin Pharmaceutical Inc. has a 1-year low of $73.45 and a 1-year high of $102.49.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported $0.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.33. The firm had revenue of $303.70 million for the quarter, compared to analysts’ expectations of $292.58 million. BioMarin Pharmaceutical had a negative return on equity of 8.54% and a negative net margin of 46.22%. BioMarin Pharmaceutical’s revenue was up 28.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.53) EPS. Analysts expect that BioMarin Pharmaceutical Inc. will post ($0.81) EPS for the current year.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/05/26/jean-jacques-bienaime-sells-5000-shares-of-biomarin-pharmaceutical-inc-bmrn-stock-2.html.

BMRN has been the topic of a number of research reports. Zacks Investment Research raised shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, February 1st. Nomura initiated coverage on shares of BioMarin Pharmaceutical in a research note on Wednesday, March 1st. They issued a “neutral” rating on the stock. Wedbush reissued a “neutral” rating and issued a $102.00 price objective on shares of BioMarin Pharmaceutical in a research note on Wednesday, February 8th. Instinet initiated coverage on shares of BioMarin Pharmaceutical in a research note on Wednesday, March 1st. They issued a “neutral” rating and a $93.00 price objective on the stock. Finally, Cowen and Company reissued an “outperform” rating and issued a $150.00 price objective on shares of BioMarin Pharmaceutical in a research note on Wednesday, March 15th. Eight research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $111.77.

A number of institutional investors have recently modified their holdings of the company. Xact Kapitalforvaltning AB bought a new position in shares of BioMarin Pharmaceutical during the third quarter worth $1,841,000. Highbridge Capital Management LLC boosted its position in shares of BioMarin Pharmaceutical by 212.9% in the third quarter. Highbridge Capital Management LLC now owns 116,700 shares of the biotechnology company’s stock worth $10,797,000 after buying an additional 79,400 shares in the last quarter. Two Sigma Advisers LP bought a new position in shares of BioMarin Pharmaceutical during the third quarter worth $4,651,000. United Services Automobile Association boosted its position in shares of BioMarin Pharmaceutical by 5.7% in the third quarter. United Services Automobile Association now owns 31,089 shares of the biotechnology company’s stock worth $2,876,000 after buying an additional 1,682 shares in the last quarter. Finally, Dynamic Capital Management Ltd boosted its position in shares of BioMarin Pharmaceutical by 60.4% in the third quarter. Dynamic Capital Management Ltd now owns 25,577 shares of the biotechnology company’s stock worth $2,366,000 after buying an additional 9,627 shares in the last quarter. 97.78% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

12 Month Chart for NASDAQ:BMRN

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.